|
Post by gamblerjag on Apr 30, 2015 1:02:17 GMT -5
good point...
|
|
|
Post by gwb on Apr 30, 2015 1:14:41 GMT -5
a) The number 1M, has this been rounded up to whole number? b) Sales starting Feb, supposed ending 3/30 for Q1, right? Not 4/30? If it is 2 months for 1M Euro sale, that should be considered as beating estimate and pps should be up? Yes the Qty ended March 31, 2015 . It could have been rounded down to 1 million Euros ( about 1.10 in USD for each Euro )Either way it's double the reported $ 568,000 USD . MNKD first quarter results should be interesting . If they count all shipped product to SNY as sales then the numbers should much greater . I really believe in a few years this will be at least 1 Billion USD per Qty .
|
|
|
Post by jay1ajay1a on Apr 30, 2015 1:17:44 GMT -5
PRESS RELEASE Afrezza® a new rapid-acting inhaled insulin therapy (licensing agreement with MannKind), was launched in the U.S. in February 2015. Sales of the product were €1 million in the first quarter. (Which = $1,108,535.00 in US dollars) en.sanofi.com/Images/38778_20150430_Q1RESULTS_EN.pdf
|
|
|
Post by tchalaa on Apr 30, 2015 1:25:23 GMT -5
Afrezza sales in the first quarter $1000,000 beats 100% RBC analyst forecast $500,000 & 200% IMS estimate
|
|
|
Post by doodyfree on Apr 30, 2015 1:26:55 GMT -5
1 MIL euro == 1.1 MIL USD
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 30, 2015 1:28:09 GMT -5
so is this 1 million euros total sales of afrezza or the 65% of the sales that SNY gets?
|
|
|
Post by doodyfree on Apr 30, 2015 1:31:38 GMT -5
Likely total net sale; not 65%.
|
|
|
Post by eddiemoy on Apr 30, 2015 1:33:52 GMT -5
Question is how they book 7m for toujeo when it was approved in April?
|
|
|
Post by eddiemoy on Apr 30, 2015 1:37:47 GMT -5
Oops, toujeo was approved 2/25 by fda. Wonder how they sell lots more than afrezza which was approved last year!
|
|
|
Post by tigiron on Apr 30, 2015 1:45:46 GMT -5
In the report, toujoe is being mentioned as (among) significant launch, afrezza just plain launch. Wonder what is the difference?
|
|
hd99
Newbie
Posts: 18
|
Post by hd99 on Apr 30, 2015 1:48:55 GMT -5
"Toujeo®, a next-generation basal insulin used to treat adults with type 1 and type 2 diabetes, was granted approval by the FDA in late February. Full launch activities in the U.S. market commenced at the end of March and included Toujeo® COACH, a customized patient support program that offers tailored information and services for patients with diabetes. Sales of the product were €7 million in the first quarter which primarily reflected wholesaler demand in advance of the launch."
|
|
|
Post by eddiemoy on Apr 30, 2015 1:57:55 GMT -5
Exubura did total 12m in first 9months. Let's see if we can beat that by next q or when we do full launch!
|
|
|
Post by tigiron on Apr 30, 2015 2:32:47 GMT -5
The other more important point: For corporate accounting, what is the practice for treating coupons and discounts? Are they still counted within reported sales number? This factor can potentially double the $1M corporate sale to a $2M retail, hence inflate scripts even more (1st script fill free, then max discount $150). Anybody has any expertise regarding this?
On the other hand, the 1M euro can also just reflect wholesalers' inventory?
|
|
|
Post by tigiron on Apr 30, 2015 2:45:32 GMT -5
How does this compare to Lantus launch? 2Q01 8M Euro 2001 58 M Were these numbers US market or world wide (this maybe a factor of 3)? Anybody interested in putting them into the right perspective
|
|
|
Post by benh on Apr 30, 2015 4:22:49 GMT -5
The 1MM is wholesaler shelf filling. Equates to around 5.5k boxes. Or around 3k Rx capacity. This shows that the take up is exactly as SNY expected. Which shows that all is going to plan. What is going to effect the short term price is if that plan for the next 12months is, 1/ revealed and 2/ sufficient to get the PPS above where we are now. Without some buying pressure, we see new 52wk lows.
At the moment, MNKD will look to take around $18-20MM for manufacturing from Q1. The profit share from the partnership is a tricky one as they may not realize anything from it for a while and needs someone above my paygrade to work that one out. As it currently stands, it wouldn't be much more than 250k in the best case scenario.
Next components are due. 2:00 pm CET (8:00 am EST): Presentation
2:30 pm CET (8:30 am EST): Live audio webcast
|
|